



## Relationship between Gastrointestinal Tumors and the Immune Microenvironment

Guest Editor:

**Dr. Ximing Xu**

1. Cancer Center, Renmin  
Hospital of Wuhan University,  
Wuhan, China  
2. Faculty of Medicine, Wuhan  
University, Wuhan, China

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### Message from the Guest Editor

Dear Colleagues,

The microenvironment of gastrointestinal tumors influences tumor initiation, progression, metastasis, and drug resistance through dynamic interactions with cancer cells. A number of therapies have been developed to target the immune microenvironment of tumors, such as checkpoint blockade and chimeric antigen receptor (CAR) T-cell therapy. Although these treatments offer hope to patients with advanced cancer, their side effects cannot be ignored. Therefore, more research is needed to elucidate the composition and main regulators of the immune microenvironment of gastrointestinal tumors and the interactions between gastrointestinal tumors and their immune microenvironment in order to develop more precise, safe and effective immunotherapeutic approaches to improve patient prognosis.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI